Overview

The Minnesota Society of Clinical Oncology convened some of the most well-regarded experts to share cutting-edge information, including implications of molecular testing on HER2+/HER2- breast cancer, sentinel node biopsies post neoadjuvant therapy, as well as groundbreaking research findings on the use of immunotherapy for acute lymphocytic leukemia as presented by our Hematology/Oncology Fellow and Resident Recognition Award recipient. 

This event was hosted by the Minnesota Society of Clinical Oncology—a Chapter Member of the Association of Community Cancer Centers. 

Continuing Education:

MSCO 2021 [Virtual] Spring Conference

April 15, 2021 | 6:00 - 7:45 PM CT

This educational activity is jointly provided by AXIS Medical Education and the Minnesota Society of Clinical Oncology (MSCO).

Target Audience

This activity is intended for all members of the interprofessional cancer care team including physicians, nurses, nurse practitioners, pharmacists, physician assistants, managers, billers/coders, and social workers.   

Overview

This educational activity provides updated information on the management of breast cancer, particularly advances in surgical treatment for breast cancer and new options in the treatment of hormone receptor-positive breast cancer. Participants will review emerging evidence and changes in practice that can inform the delivery of optimal care for their patients. The activity is of interest to all members of the cancer care team who are interested in learning about current advances in breast cancer research and patient care.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. Discuss recent advancements in surgical treatment for breast cancer.
  2. Describe updated options for treating patients with hormone receptor-positive breast cancer.
  3. Examine treatment options to help individualize care for patients with breast cancer.
  4. Explain management options for patients with breast cancer so that they can share in the decision-making process.
Agenda 

6:00 PM

Welcome and Introductions Samith Kochuparambil, MD President, Minnesota Society of Clinical Oncology

6:05 PM

Emerging Concepts in the Surgical Management of Breast Cancer Kelly K. Hunt, MD University of Texas MD Anderson Cancer Center

6:50 PM

Outstanding Fellow Presentation University of Minnesota

7:00 PM

State-of-the-Art Management of Stage I-III Hormone Receptor-Positive Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute

7:45 PM

Closing Remarks

ACCREDITED CONTINUING EDUCATION

Accreditation Statement

Jointly Accredited Provider Logo

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Minnesota Society of Clinical Oncology (MSCO). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

image

Credit Designation for Physicians AXIS Medical Education designates this activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit Designation for Nursing AXIS Medical Education designates this continuing nursing education activity for 1.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

Name of Faculty or Presenter/PlannerReported Financial Relationship
  

Kelly K. Hunt, MD

Research Grants: CairnSurgical, Inc.; Eli Lilly and Company; Lumicell, Inc.; and OncoNano Medicine, Inc.

Advisory Board: Armada and Merck & Co.

Eric P. Winer, MD

Consultant: Athenex; Carrick Therapeutics; G1 Therapeutics; Genentech/Roche; Genomic Health; Gilead Sciences, Inc; GlaxoSmithKline; Jounce Therapeutics, Inc; Leap Therapeutics; Lilly USA;  Novartis Pharmaceuticals Corp; Seattle Genetics, Inc; Syros Pharmaceuticals, Inc; and Zymeworks, Inc.

Contracted Research: Genentech /Roche.

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

Name of Planner/Manager/ReviewerReported Financial Relationship
  

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Balkrishna Jahagirdar, MD

Nothing to disclose

Samith Kochuparambil, MD

Nothing to disclose

Dee Morgillo, MEd., MT (ASCP) CHCP

Nothing to disclose

Nicole Rodin

Nothing to disclose

Ronald Viggiani, MD

Nothing to disclose

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

  • Attend/participate in the educational activity and review all course materials.
  • Complete the CE Declaration form online by 11:59 PM ET within 14 days of the conclusion of each activity. Instructions will be provided. If you do not enter the online portal by the above date, you will not be able to retrieve your statement of participation.  
  • Upon successful completion of the online form, your statement of completion will be presented to you to print.

Speakers

Samith Kochuparambil, MD

Board President, Minnesota Society of Clinical Oncology; Oncologist/Hematologist, Minnesota Oncology Hematology, PA - Minneapolis Clinic

Kelly Hunt, MD

Chief, Surgical Breast Oncology, MD Anderson

Eric Winer, MD

Professor, Harvard Medical School, Dana Farber Cancer Institute

Poster Presentations

As part of its Outstanding Hematology/Oncology Fellow and Resident Recognition Competition, the Minnesota Society of Clinical Oncology is pleased to share the research findings of its 2021 winning poster presentations.

Click here to see the posters.

Sessions

Key:

Complete
Failed
Available
Locked
msco
04/15/2021 at 7:00 PM (EDT)   |  150 minutes
04/15/2021 at 7:00 PM (EDT)   |  150 minutes
MSCO 2021 Virtual Spring Conference Evaluation
16 Questions
16 Questions You must complete the evaluation and declare CE by 11:59 PM ET on April 29, 2021. If you do not complete the evaluation by that date, you will not be able to retrieve your statement of participation. Upon successful completion of the evaluation, in the next section select "Claim Medical Credits", select the credit type, and enter the number of credits you wish to claim. Your statement of completion will be presented to you to print/save.
CME/CNE/Certificate of Participation
Up to 1.50 medical credits available  |  Certificate available
Up to 1.50 medical credits available  |  Certificate available CE credits available for the following sessions: Emerging Concepts in the Surgical Management of Breast Cancer State-of-the-Art Management of Stage I-III Hormone Receptor-Positive Breast Cancer
Presentation Slides
Emerging Concepts in the Surgical Management of Breast Cancer
Open to download resource.
Open to download resource.
Mechanisms of immunoevasion in acute lymphoblastic leukemia
Open to download resource.
Open to download resource.
State-of-the-Art Management of Stage I-III Hormone Receptor-Positive Breast Cancer
Open to download resource.
Open to download resource.

How to Register

You must have a State Society or ACCC account to register for this event, which will enable you to register for future events and courses with just one click.

If You DO NOT Have an Account: 

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.”
  • Click the green “Log In” button, then follow the proceeding steps, below. 

State Society and ACCC Members:

  • Click "Reset Password" and you will receive an email with a link to update your password. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
  • If you do not receive an email or need assistance with resetting your password, please contact membership@accc-cancer.org.

Non-members:

  •  Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
  • Click “eLearning” at the top of your profile page to go back to the eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
  • The green box in the upper right corner of this page will indicate “You are registered!” 

If You Have an Account: 

  • Please click the “Log In” button on the right side of this screen. You will be taken to the main login page that displays your email and password. 
  • Click the “Log in” button.
  • You will be automatically redirected back to the event page, and the green box in the upper right corner will say that “You are registered!” 

PRO TIP: If you save your password to your computer and remain logged in, you can register for additional events and courses in a matter of seconds—with just one click! 

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the event. 

*If you are employed by a pharmaceutical/device manufacturer, consulting, or technology company, please contact  April Gascon  for registration information. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this event. For assistance with registration or if you do not receive an email, please contact  registration@accc-cancer.org.

Resource Center

Platinum Premier Member

image
Bristol Myers Squibb
• Explore BMS Virtual Booth! 
• BMS Access Support 
• Learn About I-O Combination Treatment Options
Rigel Pharmaceuticals
• TAVALISSE
• Patient Website
• BJH Publication 
• TAVALISSE Resources

Platinum Members

image
Beigene
• Brukinsa (zanubrutinib)
Exelixis
Cabometyx 
Full Prescribing Information 
Access Services
G1 Therapeutics
Cosela website
G1 to One HCP Brochure
G1 to One Patient Brochure 
Patient website
Incyte
Incyte

Merck
• Merck
Pfizer
• Breast Cancer
• Pfizer Oncology
• Pfizer Oncology Together
• This is Living with Cancer

Gold Members

image


Abbvie
Venclexta
AstraZeneca
• CALQUENCE® (acalabrutinib) US HCP Website 
• LYNPARZA® (olaparib) US HCP Website  
• ENHERTU® (fam-trastuzumab deruxtecan-nxki) US HCP Website -
Click to see complete Prescribing Information
  

Daiichi Sankyo
Daiichi Sankyo 

Genentech 
• Genentech Access Solutions
Lilly
Verzenio
• Retevmo
Cyramza
Natera
Signatera
Altera

Novartis 
• Novartis Corporate Website
• PIQRAY® (alpelisib) HR+/HER2- Advanced Breast Cancer Treatment | HCP
• KISQALI® (ribociclib) Treatment: HR+/HER2- mBC | HCP
Oncopeptides
• Pepaxto 
• On Course with Oncopeptides  
• U.S. Press Release 

Pharmacyclics 
• IMBRUVICA® (Ibrutinib) Clinical Information 1 
IMBRUVICA® (Ibrutinib) Prescribing Information 
IMBRUVICA® (Ibrutinib) Patient Support Information 
Regeneron
LIBTAYO®
Regeneron

Sanofi
Sanofi
Takeda 
• Ninlaro 
• Alunbrig 
• Iclusig 


MSCO Corporate Member Contact Information (PDF)

Already registered?
Log in to access.

Log In